Paracrine-mediated osteoclastogenesis by the osteosarcoma MG63 cell line: is RANKL/RANK signalling really important?

Systemic RANK-Fc protein therapy is efficacious against primary osteosarcoma growth in a murine model via activity against osteoclasts

(2015) Toru Akiyama et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

RANK-Fc inhibits malignancy via inhibiting ERK activation and evoking caspase-3-mediated anoikis in human osteosarcoma cells

(2010) Toru Akiyama et al.   CLINICAL & EXPERIMENTAL METASTASIS

Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling

(2010) Misuzu Yamashita et al.   REGULATORY PEPTIDES

Prostaglandins in bone: bad cop, good cop?

(2010) Katherine A. Blackwell et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

The effect of selective cyclooxygenase-2 inhibitor on human osteoclast precursors to influence osteoclastogenesis in vitro

(2009) Masayuki Kawashima et al.   Modern Rheumatology

The Src Inhibitor AZD0530 Reversibly Inhibits the Formation and Activity of Human Osteoclasts

(2009) T. J. de Vries et al.   MOLECULAR CANCER RESEARCH

Osteoclast–osteoblast communication

(2008) Koichi Matsuo et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Functions of RANKL/RANK/OPG in bone modeling and remodeling

(2008) Brendan F. Boyce et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Pathway crosstalk between Ras/Raf and PI3K in promotion of M‐CSF‐induced MEK/ERK‐mediated osteoclast survival

(2008) Elizabeth W. Bradley et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

The cell biology of bone metabolism

(2008) H K Datta et al.   JOURNAL OF CLINICAL PATHOLOGY

Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte–osteoclast differentiation via induction of VEGF

(2008) HJ Knowles et al.   JOURNAL OF PATHOLOGY

VEGF enhancement of osteoclast survival and bone resorption involves VEGF receptor-2 signaling and β3-integrin

(2008) Q YANG et al.   MATRIX BIOLOGY

Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway

(2008) T. Akiyama et al.   MOLECULAR CANCER THERAPEUTICS

Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro

(2007) H Michael et al.   BRITISH JOURNAL OF PHARMACOLOGY